Janssen

Remicade

Manufacturer:

Janssen

Remicade HCPCS:

J1745

HCPCS Code Descriptor:

Injection, infliximab, excludes biosimilar, 10 mg

Category:

J Code

Remicade NDCs:

57894-0030-01, 57894-0160-01

Primary Type:

Immunology:Anti-TNF

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Remicade:

Remicade is an Immunology:Anti-TNF drug manufactured by Janssen and administered via the Intravenous route of administration. The J Code: J1745 is aligned to the drug Remicade.

Remicade is a prescription medication that works by affecting a certain protein in the body's immune system that causes inflammation. This protein is called the TNF-Alpha protein and has been identified as being involved in multiple inflammatory and auto-immune diseases. Remicade is administered via an intravenous infusion. As of 2023, there are multiple biosimilar drugs for Remicade. These include Inflectra (Q5103), Renflexis (Q5104), and Avsola (Q5121). Johnson and Johnson manufactures Remicade and offers a patient assistance site.

ACCESS PRICING AND MORE BY REGISTERING

J1745 Added Date:

January 1, 2000

J1745 Effective Date:

January 1, 2017

J1745 Termination Date:

HCPCS Active

Remicade billing and coding information can be found through Janssen at the link below:
Remicade patient assistance information can be found through The Johnson and Johnson Patient Assistance Foundation at the URL: https://www.jjpaf.org/medications/
Remicade prescribing information can be found at the link below:
Information regarding Remicade’s side effects can be found at MedlinePlus